CN106831538B - The preparation method of tropsch imatinib intermediate - Google Patents
The preparation method of tropsch imatinib intermediate Download PDFInfo
- Publication number
- CN106831538B CN106831538B CN201710046205.7A CN201710046205A CN106831538B CN 106831538 B CN106831538 B CN 106831538B CN 201710046205 A CN201710046205 A CN 201710046205A CN 106831538 B CN106831538 B CN 106831538B
- Authority
- CN
- China
- Prior art keywords
- preparation
- benzyl
- compound according
- amine
- ketone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000005517 L01XE01 - Imatinib Substances 0.000 title abstract description 13
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title abstract description 13
- 229960002411 imatinib Drugs 0.000 title abstract description 13
- 150000002466 imines Chemical class 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 230000009467 reduction Effects 0.000 claims abstract description 11
- 150000002576 ketones Chemical class 0.000 claims abstract description 10
- 150000001412 amines Chemical class 0.000 claims abstract description 9
- MKIZSVUTUWPHMD-UHFFFAOYSA-N 1-benzyl-4-methyl-3,6-dihydro-2h-pyridine Chemical compound C1CC(C)=CCN1CC1=CC=CC=C1 MKIZSVUTUWPHMD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000012467 final product Substances 0.000 claims abstract description 6
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 6
- 239000007858 starting material Substances 0.000 claims abstract description 6
- 238000001953 recrystallisation Methods 0.000 claims abstract description 5
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- -1 alkene Hydrocarbon Chemical class 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 235000002906 tartaric acid Nutrition 0.000 claims description 6
- 239000011975 tartaric acid Substances 0.000 claims description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical group C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000003647 oxidation Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 150000001336 alkenes Chemical class 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 abstract description 4
- 238000012545 processing Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 8
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000012450 pharmaceutical intermediate Substances 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- LUOGVMPUQUBQTC-UHFFFAOYSA-N hydron;1-methylpiperidin-3-amine;dichloride Chemical compound Cl.Cl.CN1CCCC(N)C1 LUOGVMPUQUBQTC-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of preparation methods that tropsch imatinib intermediate is new, more particularly to tropsch imatinib intermediate (3R, 4R) -1- benzyl-N, the preparation method of 4- lupetidine -3- amine dihydrochloride, with 1- benzyl -4- methyl-1, 2, 3, 6- tetrahydropyridine is as starting material, by one-step method by olefin oxidation at ketone II, after forming imines III with amine later, amine is formed with asymmetric reduction imines, cis-structure IV is obtained by recrystallization removal transisomer, finally final product (3R is obtained with chiral resolution, 4R) -1- benzyl-N, 4- lupetidine -3- amine dihydrochloride I.The process innovation of this preparation method, shortens processing step, greatly improves asymmetric compound synthesis yield, takes a firm foundation for industrialized production.
Description
Technical field
The present invention relates to a kind of preparation methods of tropsch imatinib intermediate, and in particular to (3R, 4R) -1- benzyl-N, 4- bis-
The preparation method of methyl piperidine -3- amine dihydrochloride.
Background technique
JAK/STAT is a kind of important cytokine signaling conduction path, with disease in the blood system, tumour, rheumatoid
Many diseases such as arthritis and psoriasis are related.The JAK inhibitor tropsch imatinib of Pfizer (Pfizer) company research and development
(Tofacitinib, structure see below formula) energy selective depression JAK3 kinases, on November 6th, 2012 by U.S.'s food and drug
Management board (FDA) is by assessment of risks and mitigates tactful (REMS) approval, for treat the activities of adults phase and to methotrexate (MTX) it is anti-
It answers in bad to severe rheumatoid arthritis (rheumatoid arthritis, RA) patient.
As tropsch imatinib important intermediate (3R, 4R) -1- benzyl-N, 4- lupetidine -3- amine dihydrochloride (I),
The development of its synthesis technology is worth chemist research, reports condition survey for the substance at present, consults the change
It closes in object synthetic method, wherein patent WO2010123919A2 is reported:
The patent, as starting material, by amine ester exchange reaction, forms pyrrole with benzyl bromine by 3- amino-4-methylpyridine
Pyridine salt, the salt first use sodium borohydride reduction, are then reduced into piperidine ring with platinum oxide, then restore to obtain most by tetrahydrochysene lithium aluminium
Product.Costly metallic reducing agent platinum oxide, while the use of tetrahydrochysene lithium aluminium are not used only for this method, undoubtedly increase big industry
Security risk in production.And this method does not refer to chiral synthesis, final product and there are four types of isomers, reduces optical voidness
Degree, also reduces ultimate yield.
And refer to that route is as follows in document J.Med.Chem.2008,51,8012-8018:
The route has equally used expensive 5% rhodium C catalyst of go back original reagent, while adding hydrogen with hydrogen, increases
Operation difficulty.And final step reduction has equally used tetrahydrochysene lithium aluminium.
Summary of the invention
Purpose: in order to overcome the deficiencies in the prior art, the present invention provides a kind of preparation of tropsch imatinib intermediate
Method, with 1- benzyl -4- methyl-1,2,3,6- tetrahydropyridines are as starting material, by one-step method by olefin oxidation at ketone
(II), after forming imines (III) with amine later, amine is formed with asymmetric reduction imines, trans-isomerism is removed by recrystallization
Body obtains cis-structure (IV), finally obtains final product (3R, 4R) -1- benzyl-N, 4- lupetidine -3- with chiral resolution
Amine dihydrochloride (I).The process innovation of this method, shortens processing step, avoids the use of these hazardous agents of tetrahydrochysene lithium aluminium,
Asymmetric compound synthesis yield is greatly improved with asymmetric reduction simultaneously, is taken a firm foundation for industrialized production.
Technical solution: in order to solve the above technical problems, the technical solution adopted by the present invention are as follows:
A kind of preparation method of the pharmaceutical intermediate of tropsch imatinib, the tropsch imatinib intermediate are (3R, 4R) -1- benzyl
Base-N, 4- lupetidine -3- amine dihydrochloride, molecular structural formula are as follows:
Synthetic route is as follows:
Specifically includes the following steps:
Step 1) compound II passes through trimethyl silicon substrate trifluoro sulfonic acid by 1- benzyl -4- methyl-1,2,3,6- tetrahydropyridine
Under ester effect, under the catalysis of ketone catalytic reagent, one-step method is direct oxidation into ketone compounds II；
Step 2) compound II and methylamine form group with imine moiety III；
Step 3) group with imine moiety III is obtained cis- by asymmetric reduction after being restored by 3-sec-butyl lithium borohydride: anti-
Formula is configured as 90:10, forms cis-isomer IV by hydrochloric acid salt refining；
Step 4) cis-isomer IV under alkalinity effect by chiral selectors fractionation, by salt intermediate V, one
Pot method forms final tropsch imatinib intermediate (3R, 4R) -1- benzyl-N, 4- lupetidine -3- amine dihydrochloride (I).
In step 1), ketone catalytic reagent be cyclohexanone, acetone, one or more of 4- heptanone mixed keton, preferably
Cyclohexanone, reaction dissolvent are methylene chloride, chloroform, one of acetonitrile or two or more mixed solvents, preferably methylene chloride,
Reaction temperature is -30--10 DEG C.
In step 2), reaction dissolvent is tetrahydrofuran, toluene, ethyl alcohol, one of isopropanol or two or more mixing
Solvent, preferably tetrahydrofuran, reaction temperature are 10-30 DEG C.
In step 3), reaction dissolvent is tetrahydrofuran, and dioxane, one of acetonitrile or two or more mixing are molten
Agent, preferably tetrahydrofuran, reaction temperature are -10-70 DEG C.
In step 4), reaction dissolvent includes methanol, ethyl alcohol, one of isopropanol or two or more mixed solvents, excellent
Select methanol；
Chiral selectors are L- bis- to one of toluyl tartaric acid, L- dibenzoyl tartaric acid, tartaric acid
Or two or more mix reagents, preferential L- bis- is to toluyl tartaric acid；
Alkali used includes one or more of sodium hydroxide, potassium hydroxide, lithium hydroxide mixed base, reaction temperature
5-25℃。
The utility model has the advantages that the preparation method of tropsch imatinib intermediate provided by the invention, with 1- benzyl -4- methyl-1,2,3,
6- tetrahydropyridine is as starting material, by one-step method by olefin oxidation at ketone (II), after forming imines (III) with amine later,
Amine is formed with asymmetric reduction imines, cis-structure (IV) is obtained by recrystallization removal transisomer, finally uses hand
Property splits to obtain final product (3R, 4R) -1- benzyl-N, 4- lupetidine -3- amine dihydrochloride (I).The technique of this method is created
Newly, processing step is shortened, avoids the use of these hazardous agents of tetrahydrochysene lithium aluminium, while greatly improving not with asymmetric reduction
Symmetrical compound synthesis yield, takes a firm foundation for industrialized production.
Specific embodiment
The present invention will be further explained combined with specific embodiments below.
A kind of preparation method of the pharmaceutical intermediate I of tropsch imatinib, chemical structural formula are as follows:
The preparation method is as follows: with 1- benzyl -4- methyl-1,2,3,6- tetrahydropyridines pass through one-step method as starting material
Olefin oxidation is obtained into ketone compounds II at ketone, after forming group with imine moiety III with amine later, with asymmetric reduction imines
Formed amine, by recrystallization removal transisomer obtain cis-structure IV, finally with chiral resolution obtain final product (3R,
4R) -1- benzyl-N, 4- lupetidine -3- amine dihydrochloride I to get；
Synthetic route is as follows:
Embodiment one: by raw material 1- benzyl -4- methyl-1,2,3,6- tetrahydropyridine (187mg) is dissolved in methylene chloride
(10mL), the dichloromethane solution of trimethyl silicon substrate trifluoro sulphonic acid ester (1.1g) is added at -20 DEG C of nitrogen protection, and catalysis is added
The cyclohexanone of amount, is stirred to react and middle control reaction is to fully reacting, and column chromatographs to obtain compound II.(yield 89%).
Embodiment two: compound II (17.6g) and 50ml tetrahydrofuran, nitrogen protection, cooling are sequentially added to there-necked flask
It to 15 DEG C, is added dropwise methylamine hydrochloride (7g), controls 15-20 DEG C of temperature reaction, middle control to fully reacting.It direct plunges into next step.
Embodiment three: being added 3-sec-butyl lithium borohydride (19.8g) after above-mentioned solution is cooled to 0 DEG C, and stirring is a little while
After to be warming up to back flow reaction complete, pour into ice saturated ammonium chloride solution, be extracted with dichloromethane, merge organic phase, dry rotation
It is dry to obtain crude product, crude product is dissolved in ethyl acetate, the ethyl acetate solution stirring of HCl is added, solid, filtering, solid is precipitated
It is washed to obtain cis-compound IV with ethyl acetate.(two step yields 68%)
Example IV: compound IV (34g) is dissolved in 150g water, is adjusted PH=11 with 30%NaOH solution, is used acetic acid
Ethyl ester extraction, organic phase drying is spin-dried for being dissolved in methanol after obtaining unhindered amina, and after being cooled to 5 DEG C, L- bis- is added to methylbenzene first
Salt is obtained by filtration in acyl tartaric acid (15.78g), stirring and crystallizing.The salt is dissolved in 150g water, adjusts PH with 30%NaOH solution
=11, it is extracted with ethyl acetate, organic phase is dry to be spin-dried for obtaining unhindered amina, and ice-water bath controls temperature at 5-20 DEG C, HCl is added dropwise
Ethyl acetate solution, crude product is obtained by filtration in stirring and crystallizing, and crude product is refining to obtain fine work I with dehydrated alcohol.(yield 45%)
The above is only a preferred embodiment of the present invention, it should be pointed out that: for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (9)
1. a kind of preparation method of compound, which is characterized in that the chemical structural formula of the compound is as follows:
The preparation method is as follows: with 1- benzyl -4- methyl-1,2,3,6- tetrahydropyridines are as starting material, by one-step method by alkene
Hydrocarbon is oxidized to ketone and obtains ketone compounds II, after forming group with imine moiety III with amine later, is formed with asymmetric reduction imines
Amine obtains cis-structure IV by recrystallization removal transisomer, finally obtains final product (3R, 4R)-with chiral resolution
1- benzyl-N, 4- lupetidine -3- amine dihydrochloride I to get；
Synthetic route is as follows:
Specifically includes the following steps:
Step 1) is with 1- benzyl -4- methyl-1, and 2,3,6- tetrahydropyridines are raw material, in Me3SiSO3CF3With the work of ketone catalytic reagent
Under, oxidation reaction obtains ketone compounds II；
Step 2) compound II and methylamine form group with imine moiety III；
Step 3) group with imine moiety III is obtained cis-: trans- structure by asymmetric reduction after being restored by 3-sec-butyl lithium borohydride
Type is 90:10, forms cis-isomer IV by hydrochloric acid salt refining；
Step 4) cis-isomer IV is split under alkali effect by chiral selectors, by salt intermediate V, one kettle way shape
At (3R, 4R) -1- benzyl-N, 4- lupetidine -3- amine dihydrochloride I to get.
2. the preparation method of compound according to claim 1, it is characterised in that: in step 1), ketone catalytic reagent is hexamethylene
One or more of ketone, acetone, 4- heptanone.
3. the preparation method of compound according to claim 1, it is characterised in that: in step 1), reaction dissolvent is dichloromethane
One of alkane, chloroform, acetonitrile or two or more mixed solvents, reaction temperature are -30 to -10 DEG C.
4. the preparation method of compound according to claim 1, it is characterised in that: in step 2), reaction dissolvent is tetrahydro furan
It mutters, toluene, one of ethyl alcohol, isopropanol or two or more mixed solvents, reaction temperature are 10-30 DEG C.
5. the preparation method of compound according to claim 1, it is characterised in that: in step 3), reaction dissolvent is tetrahydro furan
It mutters, one of dioxane, acetonitrile or two or more mixed solvents, reaction temperature are -10-70 DEG C.
6. the preparation method of compound according to claim 1, it is characterised in that: in step 4), reaction dissolvent is methanol, second
One or more of alcohol, isopropanol mixed solvent；5-25 DEG C of reaction temperature.
7. the preparation method of compound according to claim 2, it is characterised in that: in step 4), chiral selectors L-
One or more of two pairs of toluyl tartaric acid, L- dibenzoyl tartaric acid, tartaric acid.
8. the preparation method of compound according to claim 2, it is characterised in that: chiral selectors are L- bis- to methylbenzene
Formyl tartaric acid.
9. the preparation method of compound according to claim 2, it is characterised in that: alkali used be sodium hydroxide, potassium hydroxide,
One or more of lithium hydroxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710046205.7A CN106831538B (en) | 2017-01-22 | 2017-01-22 | The preparation method of tropsch imatinib intermediate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710046205.7A CN106831538B (en) | 2017-01-22 | 2017-01-22 | The preparation method of tropsch imatinib intermediate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106831538A CN106831538A (en) | 2017-06-13 |
| CN106831538B true CN106831538B (en) | 2019-06-25 |
Family
ID=59120068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710046205.7A Active CN106831538B (en) | 2017-01-22 | 2017-01-22 | The preparation method of tropsch imatinib intermediate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106831538B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108976164A (en) * | 2018-06-20 | 2018-12-11 | 南通常佑药业科技有限公司 | The preparation method of chiral piperidine amine compounds and the recovery method of chiral resolving agent |
| MA53162A (en) * | 2018-07-18 | 2021-05-26 | Astrazeneca Ab | XINAFOATE SALT OF JAK INHIBITOR COMPOUND |
| CN108948022B (en) * | 2018-08-16 | 2020-02-18 | 山东罗欣药业集团恒欣药业有限公司 | Synthesis method of tofacitinib |
| CN109761884B (en) * | 2019-01-30 | 2020-03-31 | 湖北扬信医药科技有限公司 | A kind of preparation method of chiral amine B and its application |
| CN109734653B (en) * | 2019-02-21 | 2020-07-14 | 北京悦康科创医药科技股份有限公司 | Resolution method of argatroban starting material isomer impurities |
| CN112552184B (en) * | 2020-12-18 | 2022-05-10 | 诚达药业股份有限公司 | Synthetic method of cyclopropyl-containing chiral amine hydrochloride |
| CN114807071B (en) * | 2022-05-11 | 2023-10-20 | 中国科学院天津工业生物技术研究所 | An enzymatic preparation method of key intermediates of tofacitinib |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1439010A (en) * | 2000-06-26 | 2003-08-27 | 辉瑞产品公司 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressants |
| CN1729192A (en) * | 2001-05-31 | 2006-02-01 | 辉瑞产品公司 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| CN105884781A (en) * | 2016-04-18 | 2016-08-24 | 山东罗欣药业集团股份有限公司 | Preparation method of tofacitinib citrate |
-
2017
- 2017-01-22 CN CN201710046205.7A patent/CN106831538B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1439010A (en) * | 2000-06-26 | 2003-08-27 | 辉瑞产品公司 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressants |
| CN1729192A (en) * | 2001-05-31 | 2006-02-01 | 辉瑞产品公司 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| CN105884781A (en) * | 2016-04-18 | 2016-08-24 | 山东罗欣药业集团股份有限公司 | Preparation method of tofacitinib citrate |
Non-Patent Citations (1)
| Title |
|---|
| An Improved and Efficient Process for the Preparation of Tofacitinib Citrate;Arijit Das et al.;《Organic Process Research & Development》;20141117;第18卷(第12期);第1714-1720页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106831538A (en) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106831538B (en) | The preparation method of tropsch imatinib intermediate | |
| CN105884781B (en) | Preparation method of tofacitinib citrate | |
| JP7703642B2 (en) | Method for synthesizing C-nucleoside compounds | |
| CN115768763B (en) | Preparation method of CDK4/6 inhibitor | |
| CN107337676A (en) | A kind of support method replaces the preparation method of cloth initiation material | |
| JP2021527703A (en) | Bribalacetam intermediate, its manufacturing method and bribalacetam manufacturing method | |
| EP3812371A1 (en) | A process for preparing brivaracetam | |
| EP3196193B1 (en) | Method for producing optically active valeric acid derivative | |
| WO2005044805A1 (en) | A novel process for preparing donepezil and its derivatives | |
| CN105111134B (en) | The method that one kind prepares (R) or (S) 3 amino piperidine dihydrochloride | |
| CN106432059A (en) | Preparation method of 3-hydroxypiperidine, preparation method of derivative of 3-hydroxypiperidine, and intermediate of 3-hydroxypiperidine | |
| CN111793016B (en) | Preparation method of larotinib intermediate and intermediate compound | |
| CN115838342A (en) | Method for asymmetrically catalytically hydrogenating aminoketone | |
| CN108530402B (en) | Preparation method of (R) -3-propyl-gamma-butyrolactone | |
| CN112430208A (en) | Preparation method of PF-06651600 intermediate | |
| EP3904333B1 (en) | Method for preparing (2s,3s)-3-amino-bicyclo[2.2.2]octane-2-carboxylate | |
| KR20040079324A (en) | New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulphonate | |
| CN109280055A (en) | Asymmetric synthesis of ergot alkaloids | |
| CN109134351A (en) | S-3-(4- aminophenyl) piperidines synthetic method | |
| CN112341413A (en) | Intermediate for synthesizing brivaracetam and preparation method thereof | |
| EP3470399B1 (en) | Method for producing optically active valeric acid derivative | |
| CN113754597B (en) | Benzhydryl piperazine compound containing linear olefin and preparation method thereof | |
| CN114380794B (en) | Preparation method of fasudil | |
| CN119751337A (en) | Preparation method of high-purity nilaparib intermediate | |
| WO2019008594A1 (en) | Continuous process for the preparation of 2-(1h-imidazol-4-yl) ethanamine and pharmaceutically acceptable salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |